Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11831191 | 0.91 | L3MBTL1 (0.54) | ALDH1A1LMNAL3MBTL1POLBCYP1A2 | |
| SCHEMBL22118370 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2ANPC1MEN1LMNA | |
| SCHEMBL133738 | 0.82 | ALDH1A1 (0.87) | ALDH1A1KMT2ANPC1MEN1LMNA | |
| SCHEMBL3256326 | 0.79 | NPC1 (0.62) | ALDH1A1KMT2ANPC1MEN1LMNA | |
| SCHEMBL124577 | 0.79 | KMT2A (0.59) | ALDH1A1KMT2ANPC1MEN1L3MBTL1 | |
| SCHEMBL1581464 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KMT2ANPC1MEN1LMNA | |
| SCHEMBL18113085 | 0.78 | KMT2A (0.55) | ALDH1A1KMT2ANPC1MEN1LMNA | |
| SCHEMBL8544332 | 0.78 | GAA (0.57) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL17433560 | 0.77 | KMT2A (0.57) | ALDH1A1KMT2ANPC1MEN1L3MBTL1 | |
| SCHEMBL17433641 | 0.77 | KMT2A (0.57) | ALDH1A1KMT2ANPC1MEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-5491152-A | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168039-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | ALDH1A1 856/4885KMT2A 2678/4885NPC1 3/4885 |
| US-20100137273-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | ALDH1A1 872/4885KMT2A 2518/4885NPC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.